[dedup-flagged] Support levels are the headline: the stock just got smacked back to its 50-day moving average near $52, which has been a reliable springboard during this 17% two-month uptrend. IV is rich at 88%, but it's actually justified — realized vol is 52%, so the 1. 38 IV/RV ratio means we're getting paid for real movement, not just fear.

The risk is the sector's fragility; biotech can gap down on a headline. Structure a defined-risk put spread: sell the $50 put (5. 2% OTM, delta ~0.

30), buy the $48 put for protection. That's a $2 wide spread; we target a $0. 60 credit for a 30% return on risk.

Max loss is contained to $140 per spread if it collapses. Verdict: The floor is tested, premium is fair — take the credit.